Compare TV & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TV | AGIO |
|---|---|---|
| Founded | 1969 | 2007 |
| Country | Mexico | United States |
| Employees | 26599 | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | N/A | 2013 |
| Metric | TV | AGIO |
|---|---|---|
| Price | $2.61 | $27.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | $5.30 | ★ $38.88 |
| AVG Volume (30 Days) | ★ 1.0M | 717.6K |
| Earning Date | 05-12-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.83% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,011,000.00 |
| Revenue This Year | N/A | $76.75 |
| Revenue Next Year | N/A | $170.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.96 | $22.24 |
| 52 Week High | $3.49 | $46.00 |
| Indicator | TV | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 31.74 | 44.32 |
| Support Level | $2.55 | $26.75 |
| Resistance Level | $2.95 | $29.37 |
| Average True Range (ATR) | 0.09 | 1.21 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 15.71 | 19.32 |
Televisa is one of the leading telecom firms in Mexico. Its cable arm, Izzi, holds networks that pass 20 million Mexican homes and provide broadband service to nearly 6 million customers. The firm is also one of the largest pay-television providers in Mexico, with nearly 4 million customers. Televisa owns Sky Mexico, the country's only satellite-TV provider, serving about 4 million customers. After merging its traditional media business into Univision, Grupo Televisa owns a 43% stake in the combined entity TelevisaUnivision. Grupo Televisa spun off several smaller businesses, including magazine publishing, three of Mexico's professional soccer teams, and Azteca Stadium in February 2024, under the name Ollamani.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.